Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron and Ribavirin Regimens in HCV Genotype 2/3
NCT00302081Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2003
- Primary completion
- Apr 2008
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response. Started Aug 2003; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00302081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302081.